文献速递淋巴瘤白血病

近四倍体与接受伊布替尼治疗的慢性淋巴细胞白血病患者的里氏转化相关

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.
PubMed 文献 · Blood Adv · 2017-08-21

在4项临床试验中,297例慢性淋巴细胞白血病患者开始伊布替尼治疗前用荧光原位杂交检测近四倍体,9例(3.0%;95%CI 1.4%-5.7%)存在近四倍体,并与Rai 3/4期、17p缺失、复杂核型及因里氏转化停药相关,其中6例发生弥漫大B细胞淋巴瘤型里氏转化。

要点

  • 297例接受伊布替尼治疗的慢性淋巴细胞白血病患者中,9例(3.0%;95%CI 1.4%-5.7%)检出近四倍体。
  • 近四倍体与Rai 3/4期(P = .03)、17p缺失(P = .03)、复杂核型(P = .01)相关。
  • 近四倍体与因里氏转化停用伊布替尼相关(P < .0001),多变量模型中HR为8.66(95%CI 3.83-19.59;P < .0001)。

核心结论

  • 近四倍体可能是接受伊布替尼治疗患者里氏转化的潜在预后标志物,值得在患者中评估。

研究设计与样本

  • 在4项临床试验中,对297例开始伊布替尼治疗前的慢性淋巴细胞白血病患者,采用荧光原位杂交检测近四倍体。

主要发现

  • 297例患者中,9例检出近四倍体(3.0%;95%CI 1.4%-5.7%)。
  • 近四倍体与Rai 3/4期(P = .03)、17p缺失(P = .03)、复杂核型(P = .01)相关。
  • 近四倍体与因里氏转化停用伊布替尼相关(P < .0001),与因慢性淋巴细胞白血病进展停药不相关(P = .41)。
  • 9例近四倍体患者中,6例发生弥漫大B细胞淋巴瘤型里氏转化。
  • 多变量模型中,近四倍体(HR 8.66;95%CI 3.83-19.59;P < .0001)和复杂核型(HR 4.77;95%CI 1.42-15.94;P = .01)是因转化停用伊布替尼的独立危险因素。

临床怎么用

  • 作者认为近四倍体可能是接受伊布替尼治疗患者里氏转化的潜在预后标志物,值得评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ibrutinib is a highly effective targeted therapy for chronic lymphocytic leukemia (CLL). However, ibrutinib must be discontinued in a subset of patients due to progressive CLL or transformation to aggressive lymphoma (Richter transformation). Transformation occurs early in the course of therapy and has an extremely poor prognosis. Thus, identification of prognostic markers associated with transformation is of utmost importance. Near-tetraploidy (4 copies of most chromosomes within a cell) has been reported in various lymphomas, but its incidence and significance in CLL has not been described. Using fluorescence in situ hybridization, we detected near-tetraploidy in 9 of 297 patients with CLL prior to beginning ibrutinib treatment on 1 of 4 clinical trials (3.0%; 95% confidence interval [CI], 1.4%-5.7%). Near-tetraploidy was associated with aggressive disease characteristics: Rai stage 3/4 (P = .03), deletion 17p (P = .03), and complex karyotype (P = .01). Near-tetraploidy was also associated with ibrutinib discontinuation due to Richter transformation (P < .0001), but not due to progressive CLL (P = .41). Of the 9 patients with near-tetraploidy, 6 had Richter transformation with diffuse large B-cell lymphoma. In a multivariable model, near-tetraploidy (hazard ratio [HR], 8.66; 95% CI, 3.83-19.59; P < .0001) and complex karyotype (HR, 4.77; 95% CI, 1.42-15.94; P = .01) were independent risk factors for discontinuing ibrutinib due to transformation. Our results suggest that near-tetraploidy is a potential prognostic marker for Richter transformation to assess in patients going on ibrutinib.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Miller CR, Ruppert AS, Heerema NA, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017. PMID: 29296799. doi:10.1182/bloodadvances.2017007302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。